Nivolumab

NASHVILLE, Tenn., Oct. 10, 2025 /PRNewswire/ -- Thyme Care and American Oncology Network (AON) announced today that nine jointly developed research abstracts have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Quality Care Symposium 2025, taking place October 10–11 in Chicago, IL. The studies underscore how the organizations' complementary expertise–AON's expansive clinical network and real-world care transformation experience, paired with Thyme Care's technology and analytics—is shaping the future of data-driven, patient-centered, value-based oncology. The studies reflect real-world insights gained from implementing the Enhancing Oncology Model (EOM), CMS's current leading oncology value-based care program, across a multi-state network of oncology practices and Medicare beneficiaries. These analyses were co-developed by AON and Thyme Care, drawing on a shared dataset representing thousands of EOM episodes from AON's multi-state clinical network. With AON representing nearly a tenth of total EOM episodes nationwide, the work provides a robust lens into broader patterns of care, cost, and outcomes. "This body of research is a powerful validation of what's possible when collaborative clinical care and data science come together," said Dr. Bobby Green, co-founder, president, and chief medical officer at Thyme Care. "Having nine abstracts accepted to ASCO Quality demonstrates the strength of our shared model, the quality of AON and Thyme Care's real-world care redesign experience, and the depth of our collaboration. Together, we're building and implementing value-based care models that reduce burden, improve outcomes, and truly reflect what matters to patients." This research reflects just one aspect of AON and Thyme Care's broader collaboration to enable value-based oncology care at scale. By combining AON's extensive patient population and care delivery expertise with Thyme Care's technology and analytics platform, the partners are delivering actionable solutions that improve quality, reduce the total cost of care, and enhance the patient experience. Their integrated approach goes beyond retrospective reporting—enabling real-time patient tracking, scenario modeling, and economic forecasting that directly inform decisions at the point of care. A full list of abstract titles and viewing details is listed below: 1. Informing Policy Design in the Enhancing Oncology Model As CMS refines the EOM and future alternative payment models, AON and Thyme Care's collaborative work reveals critical insights into how these models function in practice and where they can be improved. Five abstracts offer data-driven recommendations to reduce operational burden, improve fairness, and align cost predictions with clinical realities. Clinical Adjusters in the EOM Should Not Be Static: A Deep Dive Into HER2. Demonstrates that static cost groups fail to reflect evolving drug prices and treatment patterns, particularly in breast cancer, which has a new paradigm of "HER2-low" disease. Recommends calculating trend factors at the cancer type x clinical adjuster level. (Abstract #86) Evaluating the Derivation of Clinical Adjusters in the EOM: Claims Data vs. Practice-Reported Sources. Finds that HER2 status can be reliably derived from claims data, reducing reporting burden and improving accuracy. (Abstract #87) Evaluating the Explanatory Power of Histology as a Clinical Adjuster in EOM Lung Cancer Episodes. Shows that histology adds minimal explanatory value to benchmark variation in lung cancer, questioning its utility in reporting. (Abstract #88) Minimum Episode Volume to Reduce Stochastic Risk in the Enhancing Oncology Model. Reveals that most practices operate below a threshold needed for stable financial outcomes, advocating for minimum episode requirements or explaining to practices more clearly when they should risk pool. (Abstract #89) Assessing Episode Groupers Impact on Cost and Quality Comparisons in the Enhancing Oncology Model. Highlights the limitations of current episode groupers, which fail to capture intra-cancer variability. Recommends more clinically precise episode definitions. (Abstract #90) Improving Patient Experience Through Smarter Care Delivery For many patients—particularly those near the end of life—the burden of cancer care can be as significant as the disease itself. Drawing on AON's clinical platform capabilities and Thyme Care's value-based care enablement, these studies explore how more thoughtful treatment approaches can reduce burden and better align with patients' individual values, goals, and preferences. Real-World Data on Time Toxicity Experienced by Patients on Select Immune Checkpoint Inhibitor Regimens in Their Last Year of Life. Demonstrates that extended-interval dosing of pembrolizumab and nivolumab significantly reduces clinic visits—cutting treatment-related time toxicity in half during the last year of life. (Abstract #351) Clinical Outcomes for Patients Treated with Pembrolizumab Weight-Based Dosing in the Enhancing Oncology Model. Confirms that weight-based dosing is safe, feasible, and cost-effective across multiple cancers, with no adverse safety signals observed. (Abstract #27) Driving Policy Change for More Equitable Care Health equity sits at the core of value-based care, yet current methodologies may unintentionally penalize practices serving vulnerable populations. AON and Thyme Care's joint research identifies specific gaps that could undermine model goals and proposes actionable solutions. Impact of State Medicaid Expansion on Practice Performance in the Enhancing Oncology Model. Reveals that practices in non-expansion states may be penalized by a benchmark design that omits upward Low-Income Subsidy (LIS) adjustments for certain cancer types. (Abstract #196) Rethinking Systemic Anti-Cancer Therapy in the Last 14 Days of Life in the Era of Oral Oncology: Examines how oral therapies distort standard end-of-life quality measures and suggests that new definitions are needed for modern cancer care. (Abstract #466) Why it matters: A Vision for the Future of Cancer Care This body of work is a call to action for the oncology ecosystem. By connecting real-world clinical data from AON's multi-state network with national policy design and advanced analytics from Thyme Care, the partnership is helping reshape how cancer care is measured, reimbursed, and delivered. Together, the organizations demonstrate how value-based care can build a foundation for more compassionate, efficient, and equitable cancer care. "At American Oncology Network, we've seen firsthand how real-time data and aligned care models can improve patient outcomes and reduce cost," said Dr. Stephen "Fred" Divers, Chief Medical Officer of AON and co-author on all abstracts. "These studies demonstrate the power of collaboration between a robust clinical network and a data-driven value-based care enabler to lead the next generation of value-based oncology." About Thyme Care Thyme Care is the leading value-based care enabler, collaborating with payers and providers to transform the experience and outcomes for individuals living with cancer. The company partners with health plans, employers and risk-bearing providers to assume accountability for enhanced care quality, improved health outcomes, and reduced total cost of care. Thyme Care's approach combines a technology-enabled Care Team and seamless integration with providers, creating a hybrid collaborative care model that guides and supports the entire patient journey. Thyme Care empowers oncologists nationwide through purpose-built tech, advanced data analytics, and virtual patient engagement, driving better care and outcomes in value-based arrangements. To learn more about how Thyme Care is enabling the shift to value-based care in oncology, visit Contact Kimberly Dreisinger Thyme Care Communications [email protected] SOURCE Thyme Care WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED